Journal of Atherosclerosis and Thrombosis
Online ISSN : 1880-3873
Print ISSN : 1340-3478
ISSN-L : 1340-3478
Original Articles
Effects of Pitavastatin, a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor, on Cardio-Ankle Vascular Index in Type 2 Diabetic Patients
Yoh MiyashitaKei EndoAtsuhito SaikiNoriko BanTakashi YamaguchiHidetoshi KawanaDaiji NagayamaMasahiro OhiraTomokazu OyamaKohji Shirai
Author information

2009 Volume 16 Issue 5 Pages 539-545


Aim: A novel device has been developed for measuring the cardio-ankle vascular index (CAVI) as an indicator of arterial stiffness. In this study, we evaluated the effect of pitavastatin on CAVI in type 2 diabetic patients.
Methods: Forty-five type 2 diabetes mellitus patients with low-density lipoprotein cholesterolemia were enrolled and treated with pitavastatin 2 mg/day for 12 months. Before and after pitavastatin administration, HbA1c, serum lipids, serum malondialdehyde-LDL (MDA-LDL), urinary 8-hydroxy- 2'-deoxyguanosine (8-OHdG) and CAVI were measured.
Results: After pitavastatin treatment for 12 months, significant decreases in 8-OHdG, MDA-LDL and CAVI were observed. ΔCAVI significantly correlated with ΔMDA-LDL.
Conclusions: In type 2 diabetic patients, pitavastatin may have an oxidative stress-reducing effect, especially in a state of enhanced oxidative stress, and CAVI may be useful as a routine test for the diagnosis and therapeutic monitoring of atherosclerosis.

Information related to the author

この記事はクリエイティブ・コモンズ [表示 - 非営利 - 継承 4.0 国際]ライセンスの下に提供されています。
Previous article Next article